By using a doxycycline-inducible system to acutely activate hepatic CREBH in the setting of established obesity, IR, and hepatic steatosis, we have provided new evidence that CREBH-mediated regulation may reveal therapeutic targets for the management of obesity and related metabolic disorders. Here, CREB3L3 is linked to fatty liver disease.